Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 18/20 | 1.00 |
| ▸ | KDR | P35968 | 18/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29973354 | 0.98 | PDGFRA (0.95) | PDGFRAKDR | |
| SCHEMBL27081475 | 0.98 | PDGFRA (0.95) | PDGFRAKDR | |
| SCHEMBL7482526 | 0.94 | PDGFRA (0.89) | PDGFRAKDR | |
| SCHEMBL7489320 | 0.93 | PDGFRA (0.87) | PDGFRAKDR | |
| SCHEMBL7482808 | 0.93 | PDGFRA (0.87) | PDGFRAKDR | |
| SCHEMBL7490931 | 0.93 | PDGFRA (1.00) | PDGFRAKDRFGFR2 | |
| SCHEMBL7485268 | 0.92 | PDGFRA (0.85) | PDGFRAKDR | |
| SCHEMBL7484427 | 0.92 | KDR (1.00) | PDGFRAKDR | |
| SCHEMBL7488408 | 0.92 | KDR (0.85) | PDGFRAKDR | |
| SCHEMBL7479859 | 0.92 | PDGFRA (1.00) | PDGFRAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0860433-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BREWERY (JP) | 2002-07-03 | — | — | EP | claimed |
| US-6143764-A | ETHER DERIVATIVES OF QUINOLINE, ANTITUMOR AGENTS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-11-07 | — | — | US | claimed |
| US-20090203693-A1 | THERAPEUTIC AGENT FOR LIVER FIBROSIS | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2044939-A1 | THERAPEUTIC AGENT FOR LIVER FIBROSIS | Eisai R&D Management Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-0860433-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BREWERY (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-6143764-A | ETHER DERIVATIVES OF QUINOLINE, ANTITUMOR AGENTS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203693-A1 | THERAPEUTIC AGENT FOR LIVER FIBROSIS | HDGF, MMP1, FABP1 | PDGFRA 150/4885KDR 3906/4885FGFR2 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.